| Oct 31 |
Genelux: H2 2025 PRROC Data Is A Major Inflection Point
|
| Oct 31 |
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well
|
| Oct 29 |
Genelux started at buy by Guggenheim ahead of Olvi-vec data
|
| Oct 25 |
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp
|
| Oct 23 |
Genelux doses first subject in Phase II trial of NSCLC treatment
|
| Oct 22 |
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
|
| Oct 9 |
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
|
| Sep 3 |
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
|
| Aug 29 |
Genelux started at buy by Roth MKM ahead of Olvi-Vec readouts
|
| Aug 17 |
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
|
